FDA warns Thea Pharma that IVIZIA OTC lubricant eye drops are an unapproved and misbranded new drug.
What happened
On August 29, 2024, FDA reviewed IVIZIA labeling on ivizia.com and an Amazon storefront where the eye drops were sold without a prescription. FDA found claims that made the product intended as an ophthalmic demulcent drug and found the product did not meet OTC monograph M018. FDA also found no approved application, so it called the product an unapproved new drug and misbranded.
What FDA found
The IVIZIA eye drops are an unapproved new drug because no FDA-approved application is in effect and the product does not meet the OTC monograph for ophthalmic demulcents.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d); OTC monograph M018The product is misbranded because it is a nonprescription drug subject to section 505G but does not comply with that section and has no approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)Hyaluronic acid and trehalose are not permitted active ingredients for OTC ophthalmic demulcent drug products under M018.
OTC monograph M018; FD&C Act section 505G, 21 U.S.C. 355hWebsite claims make hyaluronic acid and trehalose active ingredients even though the label lists them as inactive.
21 CFR 201.66(b)(2)
What FDA wants
FDA asks Thea Pharma to respond in writing within fifteen working days describing corrective steps, how it will prevent recurrence, and related documentation. If it cannot finish, it must explain why and give a completion date.
Who should pay attention
- OTC eye drop brands and marketers
- contract manufacturers of ophthalmic demulcent products
- online retailers and distributors selling OTC eye care products
This is a summary. Read the original letter on fda.gov.